fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults

Sponsor
Inova Health Care Services (Other)
Overall Status
Completed
CT.gov ID
NCT01320748
Collaborator
George Mason University (Other), Georgetown University (Other)
29
2
2
23
14.5
0.6

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether drug-dependent adults who participate in a dual processing relapse prevention treatment protocol that allows for sensory-based exposure experiences over 10-weeks in outpatient treatment will show significant brain change related to diminished cue reactivity, and greater improvement in self-efficacy, anxiety, somatization, and treatment retention, as compared to the standard care patients in a relapse prevention program.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Dual Processing
  • Behavioral: Relapse Prevention
N/A

Detailed Description

The substance abuse literature consistently shows that negative emotional states and subjective stress are highly predictive of relapse and significantly influence behavioral motivation. From a neurobiological perspective, stress associated with withdrawal and substance abuse experiences stimulates chemical and hormonal changes in the brain creating a protracted hyperaroused state. Further, cognitive control resources (i.e., cognitive coping skills/relapse prevention training) have been shown to exert minimal impact on behavioral decision-making in the presence of intense affective material. Thus, implicit cognitive processes play a significant role in drug use behavior, decreasing self regulation capacities and increasing risk of. Specifically, high levels of stress can compromise prefrontal cortex functioning, with the nucleus accumbens, orbitofrontal cortex and amygdala functional changes related to increased cue reactivity.

Taken together, the current literature strongly suggests that verbally-based therapies may have limited utility as a singular form of treatment in early substance abuse recovery, as the brain may not be functionally ready for executive level processing. Instead, the multidisciplinary substance abuse literature suggests that psychosocial treatment methods need to include a range of learning approaches that allow for visual-sensory processing, in addition to traditional verbal-based processing. Integrated multi-modal interventions are needed to offer opportunities for activation of these different brain regions to facilitate cognitive-affective balance in behavioral decision-making.

Study Design

Study Type:
Interventional
Actual Enrollment :
29 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
Study Start Date :
Feb 1, 2011
Actual Primary Completion Date :
Mar 1, 2012
Actual Study Completion Date :
Jan 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dual Processing

Behavioral: Dual Processing
A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
Other Names:
  • Group Therapy
  • DP
  • Active Comparator: Relapse Prevention

    Behavioral: Relapse Prevention
    The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
    Other Names:
  • Group Therapy
  • RP
  • Outcome Measures

    Primary Outcome Measures

    1. fMRI blood-oxygenation-level-dependent (BOLD) signal change as a measure of emotional reactivity related to the visual presentation of drug-imagery. [10 weeks]

      In a subset of approximately 26 subjects, fMRI technology will be employed to examine brain structure and function change (pre-treatment and post-treatment) in the amygdaloid region, orbitofrontal cortex, in the anterior cingluate cortex (structure implicated in drug cue attention); in medial prefrontal cortex and right dorsolateral prefrontal cortex (associated with effective behavioral decision-making in substance abusers).

    Secondary Outcome Measures

    1. Heart rate during MRI scanning as a measure of emotional reactivity related to the visual presentation of drug-imagery. [10 weeks]

      Changes in heart rate related to the visual presentation of drug-imagery during MRI scanning, to assess cue reactivity differences across the treatment and control groups at two time-points (pre-intervention and post-intervention).

    2. Quality of Life Inventory (QOLI) as a measure of the subject's quality of life. [10 weeks]

      Questionnaire completed by subjects at baseline and at the end of the study. We will measure changes in Overall QOLI score and Weighted Satisfaction Profile score at the two time-points (pre-intervention and post-intervention).

    3. Brief Symptoms Inventory (BSI), as a measure of subjective craving, anxiety, and somatization [10 weeks]

      Questionnaire completed by subjects at baseline and at the end of the study. We will measure changes in Nonpatient T Score and Percentile in the 12 domains at the two time-points (pre-intervention and post-intervention).

    4. Hamilton - Depression Inventory (HAM-D) as a measure of depression. [10 weeks]

      Questionnaire completed by subjects at baseline and at the end of the study. We will measure changes in the total Hamilton depression scale score at the two time-points (pre-intervention and post-intervention).

    5. Urine specimen toxicology analysis as a measure of treatment retention. [Weekly for 10 weeks]

      Urine specimen collection and analysis to track patient drug use on a weekly basis during the 10 weeks in treatment.

    6. Blood Alcohol Level analysis as a measure of treatment retention. [Weekly for 10 weeks]

      Breathalizer test for alcohol to track patient alcohol use on a weekly basis during the 10 weeks in treatment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Study Inclusion Criteria:
    • Age < 18 years old

    • Signed informed consent for this study

    • History of chemical dependency

    • Meets Inova CATS Relapse Prevention admission criteria

    • Must have at least 60 days of sobriety prior to admission with documentation of negative drug and alcohol screening

    • Documentation of HIV negative test result (completed in the past year)

    • Willing and able to attend an out-patient drug treatment group for two hours twice a week for 10 weeks

    • Willing to complete study-required evaluations (including assessments, questionnaires, drug/alcohol testing, week 8 qualitative interview)

    • A score < 25 on the MoCA (Montreal Cognitive Assessment)

    Study Exclusion Criteria:
    • History of taking "anti-craving" medication in the past 90 days

    • Other medical illness or florid psychiatric symptoms that would render the participant inappropriate for study participation

    • History of receiving treatment for addictions other than substance use (i.e. food, gambling, sex)

    • Clinical determination of dementia or organic brain syndrome

    • History of major head injury

    • Incapable of consenting for themselves due to cognitive impairment

    • Enrollment in another study that might interfere with analysis of this study

    Additional Inclusion Criteria for fMRI sub-study:
    • Willing and able to participate in the fMRI arm of the study

    • If of childbearing capacity, must have negative screening urine pregnancy test and be willing to use birth control as specified in the consent document

    Additional Exclusion Criteria for fMRI sub-study:
    • Left-handed

    • Cardiac pacemakers or other body metals

    • Other criteria identified on the "MRI Screening Form" that would indicate that having an MRI would be unsafe

    • Pregnancy

    • Claustrophobia (for the fMRI testing)

    • Muscular or back problems that would prevent participant from being able to lie in the scanner for 90 minutes

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Georgetown Center for Functional And Molecular Imaging, Georgetown University Medical Center Washington District of Columbia United States 22057
    2 Inova Heath Services Comprehensive Addictions Treatment Services (ICATS) Falls Church Virginia United States 22042

    Sponsors and Collaborators

    • Inova Health Care Services
    • George Mason University
    • Georgetown University

    Investigators

    • Principal Investigator: Holly C Matto, PhD, Virginia Commonwealth University, School of Social Work

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Maria Hadjiyane, Senior Director Behavioral Health Adult Ambulatory Services, Inova Health Care Services
    ClinicalTrials.gov Identifier:
    NCT01320748
    Other Study ID Numbers:
    • IHS 11-001
    First Posted:
    Mar 22, 2011
    Last Update Posted:
    Nov 30, 2018
    Last Verified:
    Nov 1, 2018

    Study Results

    No Results Posted as of Nov 30, 2018